Pazopanib, brand name Votrient, is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), and KIT. Inhibitors of VEGFR like pazopanib (Votrient, GlaxoSmithKline), show activity against leiomyosarcoma, synovial sarcoma and other sarcomas including those of vascular origin. There is one supportive phase II study form EORTC. It concluded: “Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.”Pazopanib is being investigated in a large randomized placebo-controlled phase III study, which has recently completed accrual and has survival as its endpoint. The study has been expanded in order to ensure that enough events will be observed to determine whether angiogenesis inhibition can prolong survival in patients with chemotherapy-refractory advanced sarcoma: A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (PALETTE),NCT00753688.